TNF Pharmaceuticals, Inc. (TNFA) Financial Statements
Industry: In Vitro & In Vivo Diagnostic Substances
Net income was -$11.6M, or -$8.66 per diluted share. Operating activities generated -$9.1M of cash, leaving -$10.8M of free cash flow. At fiscal year end, TNF Pharmaceuticals held $41.2M in total assets against $16.4M in total liabilities, including $986,996 of cash and equivalents.
Open the full interactive TNF Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
TNF Pharmaceuticals Key Stats
| Share Price | $0.55 |
|---|---|
| Market Cap | $4.5M |
| 52-Week Range | $0.44 – $6.92 |
| Shares Outstanding | 8.2 million (basic, 2026 Q2) |
TNF Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Operating Income | -$12.3M | -$28.8M | -$15.3M | -$17.1M | -$10.2M | -$9.8M |
| Pre-Tax Income | -$12.2M | -$29.9M | -$15.2M | -$4.0M | -$23.4M | -$11.6M |
| Income Tax | $5.4M | — | — | — | — | — |
| Net Income | -$17.6M | -$29.9M | -$15.2M | -$4.0M | -$23.4M | -$11.6M |
| Diluted EPS | -$14940.00 | -$2560.66 | — | -$533.00 | -$1115.00 | -$8.66 |
TNF Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Net Income | -$2.8M | -$5.9M | -$1.2M | -$6.6M |
| Diluted EPS | -$2.50 | -$3.41 | -$0.19 | -$0.79 |
TNF Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $18.6M | $555,967 | $749,090 | $2.7M | $173,154 | $986,996 |
| Current Assets | $36.8M | $12.7M | $5.4M | $5.8M | $9.4M | $16.6M |
| Total Assets | $36.8M | $24.8M | $17.5M | $17.9M | $21.4M | $41.2M |
| Current Liabilities | $2.3M | $1.0M | $2.8M | $5.0M | $6.7M | $5.5M |
| Total Liabilities | $2.3M | $1.2M | $2.8M | $5.1M | $6.7M | $16.4M |
| Shareholders' Equity | $34.6M | $23.6M | $14.7M | $12.4M | $9.8M | $21.8M |
TNF Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$11.9M | -$19.5M | -$12.3M | -$13.0M | -$9.0M | -$9.1M |
| Cash From Investing | -$8.8M | $19.9M | $6.9M | $1.8M | -$6.1M | -$8.4M |
| Cash From Financing | $38.7M | $73,533 | $5.6M | $13.1M | $12.6M | $18.3M |
| Free Cash Flow | — | — | — | — | — | -$10.8M |
Figures from TNF Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full TNF Pharmaceuticals financials page for every line item.
TNF Pharmaceuticals Company Profile
| Ticker | TNFA |
|---|---|
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Headquarters | New York, New York |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001321834 |
Frequently Asked Questions
What was TNF Pharmaceuticals' net income in fiscal 2025?
TNF Pharmaceuticals reported net income of -$11.6M for fiscal 2025.
What was TNF Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
TNF Pharmaceuticals' diluted EPS was -$8.66 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did TNF Pharmaceuticals generate in fiscal 2025?
TNF Pharmaceuticals generated -$10.8M of free cash flow in fiscal 2025.
How many shares of TNF Pharmaceuticals are outstanding?
TNF Pharmaceuticals reported a weighted average of 8.2 million basic shares outstanding in 2026 Q2.
What is TNF Pharmaceuticals' market cap?
Based on its latest closing price, TNF Pharmaceuticals (TNFA) has a market capitalization of about $4.5M.
When does TNF Pharmaceuticals' fiscal year end?
TNF Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is TNF Pharmaceuticals headquartered?
TNF Pharmaceuticals lists its business address in New York, New York in its SEC filings.
TNF Pharmaceuticals Competitors & Similar Companies
See all 15 In Vitro & In Vivo Diagnostic Substances companies →